Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors by Lecia V. Sequist, Belinda A. Waltman, Dora Dias-Santagata,

Slides:

Advertisements

Similar presentations

Strategies to overcome resistance in NSCLC with driver mutations

Advertisements

Repeat Biopsies and the Potential Value of Biologically-Informed Acquired Resistance Therapy Lecia V. Sequist, MD, MPH Associate Professor of Medicine,

High-throughput Clinical Cancer Genotyping

Effects of AIN457, a Fully Human Antibody to Interleukin- 17A, on Psoriasis, Rheumatoid Arthritis, and Uveitis by Wolfgang Hueber, Dhavalkumar D. Patel,

Therapeutic Intervention of Ebola Virus Infection in Rhesus Macaques with the MB-003 Monoclonal Antibody Cocktail by James Pettitt, Larry Zeitlin, Do H.

T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia by Michael Kalos, Bruce.

Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLC Alexa B. Turke, Kreshnik Zejnullahu, Yi-Long Wu, Youngchul Song, Dora Dias-Santagata,

Conserved Shifts in the Gut Microbiota Due to Gastric Bypass Reduce Host Weight and Adiposity by Alice P. Liou, Melissa Paziuk, Jesus-Mario Luevano, Sriram.

Mechanisms of resistance to EGFR TKIs and related treatment strategies

The Bayh-Dole Act Turns 30 by Vicki Loise, and Ashley J. Stevens Sci Transl Med Volume 2(52):52cm27-52cm27 October 6, 2010 Published by AAAS.

First-in-Human Testing of a Wirelessly Controlled Drug Delivery Microchip by Robert Farra, Norman F. Sheppard, Laura McCabe, Robert M. Neer, James M. Anderson,

Scanning ultrasound removes amyloid-β and restores memory in an Alzheimer’s disease mouse model by Gerhard Leinenga, and Jürgen Götz Sci Transl Med Volume.

The Effect of Diet on the Human Gut Microbiome: A Metagenomic Analysis in Humanized Gnotobiotic Mice by Peter J. Turnbaugh, Vanessa K. Ridaura, Jeremiah.

Development of Personalized Tumor Biomarkers Using Massively Parallel Sequencing by Rebecca J. Leary, Isaac Kinde, Frank Diehl, Kerstin Schmidt, Chris.

Acquired Resistance to Crizotinib from a Mutation in CD74-ROS1 Mark M

Fig. 1. IL-6 is associated with resistance to EGFR TKIs and is induced by stress hormones. IL-6 is associated with resistance to EGFR TKIs and is induced.

EGFR Inhibitors in Advanced NSCLC: Who, When, and Why?

Moving Care Forward in Advanced NSCLC

Fig. 8. Gene and protein changes in ALK-dependent STING pathways in human sepsis. Gene and protein changes in ALK-dependent STING pathways in human sepsis.

Fig. 3. Antimicrobial activity is detected in diverse strains of CoNS and not predictable at the species level. Antimicrobial activity is detected in diverse.

Fig. 5 Maraba induces antitumor T cell immunity.

Treatment of Stage IV Non-small Cell Lung Cancer

Fig. 2. dAST using dPCR is robust to the presence of high concentrations of commensal bacteria due to the specificity of NA amplification. dAST using dPCR.

Fig. 4. Functional annotation of VUS in EGFR.

Fig. 1 Crohn’s disease association within the LRRK2 locus.

Fig. 1 Localized treatment of TNBC cancers kills tumor cells and minimizes the metastatic burden. Localized treatment of TNBC cancers kills tumor cells.

Fig. 2 TLR8 is aberrantly expressed on pDCs from SSc patients.

Fig. 3. Frequencies of amino acids at critical PGT121 and contact sites in the SHIV-SF162P3 challenge stock. Frequencies of amino acids at critical.

Fig. 2 Maraba treatment results in complete responses in the window of opportunity setting. Maraba treatment results in complete responses in the window.

Fig. 6 Bimodal treatment results in reduced tinnitus loudness and reduced TFI scores in human patients. Bimodal treatment results in reduced tinnitus loudness.

Fig. 8. mRIPO elicits neutrophil influx followed by DC and T cell infiltration into tumors. mRIPO elicits neutrophil influx followed by DC and T cell infiltration.

Fig. 2. GPC3 expression in normal and tumor tissues.

Expression of CD36 and psap in a TMA of human ovarian cancer patients

Meghan Campo, MD, David Gerber, MD, Justin F. Gainor, MD, Rebecca S

Fig. 4 CXCL4 potentiates TLR8-mediated activation of SSc pDCs.

Circulating Tumor DNA Identifies EGFR Coamplification as a Mechanism of Resistance to Crizotinib in a Patient with Advanced MET-Amplified Lung Adenocarcinoma

Acquired Resistance to Crizotinib in NSCLC with MET Exon 14 Skipping

Fig. 1. scRNA-seq applications in cancer medicine.

Fig. 4. MATE1 transcription in RCC.

Fig. 2. Best model fits. Best model fits. Illustration of the best model fits for the (A) basic, (B) continuous, and (C) cluster models. See Table 1 and.

Fig. 5. MasSpec Pen analysis of an HGSC tissue sample with mixed histologic composition. MasSpec Pen analysis of an HGSC tissue sample with mixed histologic.

Representative CT and PET/CT images of three patients with NSCLCs

Fig. 5 EGFR mutation status of patients with NSCLC, detected by histological examination and ARMS PCR. EGFR mutation status of patients with NSCLC, detected.

Pattern of Failure Analysis in Metastatic EGFR-Mutant Lung Cancer Treated with Tyrosine Kinase Inhibitors to Identify Candidates for Consolidation Stereotactic.

Fig. 3. The effects of DCA on hemodynamic and functional end points and their association with genetic factors (variants of the SIRT3 and UCP2 genes) that.

Fig. 3. β-AR signaling induces IL-6 in NSCLC cells via activation of PKC and CREB. β-AR signaling induces IL-6 in NSCLC cells via activation of PKC and.

Jessica J. Lin, MD, Elizabeth Kennedy, BA, Lecia V

Fig. 3 M7824 inhibits tumor growth and metastasis and provides long-term antitumor immunity. M7824 inhibits tumor growth and metastasis and provides long-term.

The Prognostic Impact of KRAS, Its Codon and Amino Acid Specific Mutations, on Survival in Resected Stage I Lung Adenocarcinoma Benjamin Izar, MD, PhD,

Lipodermatosclerosis Secondary to Pemetrexed Use

Fig. 7. Genetic ablation of UCP2 compromised the protective effect of exogenous irisin on lung IR injury. Genetic ablation of UCP2 compromised the protective.

Resisting Targeted Therapy: Fifty Ways to Leave Your EGFR

Fig. 4. The effect of single-dose rozanolixizumab on the concentration of IgG subtypes in healthy subjects. The effect of single-dose rozanolixizumab on.

Fig. 6. Analysis of SHIV-325c V1V2 envelope sequences in breakthrough infections. Analysis of SHIV-325c V1V2 envelope sequences in breakthrough infections.

Radiofrequency Ablation for Stage I Non-Small Cell Lung Cancer: Management of Locoregional Recurrence Michael Lanuti, MD, Amita Sharma, MD, Henning Willers,

Fig. 1. In vivo fates of patient-derived AML cells defined by mutational profile. In vivo fates of patient-derived AML cells defined by mutational profile.

Evaluation of clinical responses after infusion of CART19 cells

Fig. 3 CSF1 is expressed in human melanoma.

Genetic Changes in Squamous Cell Lung Cancer: A Review

Consolidated Standards of Reporting Trials flow diagram of VRC trial

Fig. 2. Clinically actionable somatic genomic alterations in various tumor types. Clinically actionable somatic genomic alterations in various tumor types.

Fig. 1. Schematic showing the shedding of tumor DNA from head and neck cancers into the saliva or plasma. Schematic showing the shedding of tumor DNA from.

Fig. 1. Iontophoretic devices used for the delivery of cytotoxic agents to solid tumors. Iontophoretic devices used for the delivery of cytotoxic agents.

The microchip-based drug delivery device and overview of study design

FGFR1 Amplification in Squamous Cell Carcinoma of The Lung

Representative CT and PET/CT images of three patients with NSCLCs

Delineating cancer evolution with single-cell sequencing

Clinicopathologic Features of NSCLC Diagnosed During Pregnancy or the Peripartum Period in the Era of Molecular Genotyping Ibiayi Dagogo-Jack, MD, Justin.

Circulating Tumor DNA Identifies EGFR Coamplification as a Mechanism of Resistance to Crizotinib in a Patient with Advanced MET-Amplified Lung Adenocarcinoma

Response and resistance to savolitinib and osimertinib in a patient with EGFR-mutant NSCLC harboring MET amplification. Response and resistance to savolitinib.

Presentation transcript:

Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors by Lecia V. Sequist, Belinda A. Waltman, Dora Dias-Santagata, Subba Digumarthy, Alexa B. Turke, Panos Fidias, Kristin Bergethon, Alice T. Shaw, Scott Gettinger, Arjola K. Cosper, Sara Akhavanfard, Rebecca S. Heist, Jennifer Temel, James G. Christensen, John C. Wain, Thomas J. Lynch, Kathy Vernovsky, Eugene J. Mark, Michael Lanuti, A. John Iafrate, Mari Mino-Kenudson, and Jeffrey A. Engelman Sci Transl Med Volume 3(75):75ra26-75ra26 March 23, 2011 Published by AAAS

Fig. 1 The frequency of observed drug resistance mechanisms. Lecia V. Sequist et al., Sci Transl Med 2011;3:75ra26 Published by AAAS

Fig. 2 Acquired genetic amplifications in drug-resistant lung tumors. Lecia V. Sequist et al., Sci Transl Med 2011;3:75ra26 Published by AAAS

Fig. 3 Drug resistance and transformation of NSCLC to SCLC. The SCLC histological phenotype was observed in five (14%) NSCLC patients who had acquired resistance. Lecia V. Sequist et al., Sci Transl Med 2011;3:75ra26 Published by AAAS

Fig. 4 EMT and acquired resistance. Lecia V. Sequist et al., Sci Transl Med 2011;3:75ra26 Published by AAAS

Fig. 5 Longitudinal evaluation of patients treated repeatedly with erlotinib. Lecia V. Sequist et al., Sci Transl Med 2011;3:75ra26 Published by AAAS